Clinical trials
for patients

The objective of this study is to evaluate whether the study drug, NILK-2301 in combination with NI-1801 or treatment as usual, has potential beneficial effects and is safe for patients with this type of cancer.

The purpose of this clinical trial is to test whether trimodulin (the trial drug) works and whether it is safe to treat people with severe community-acquired pneumonia (CAP) when given with the standard of care. The reference treatments refer to the most common treatments given to people who are hospitalized with CAP and need mechanical ventilation to breathe.

The purpose of the study is to learn more about remibrutinib in the treatment of chronic inducible urticaria and chronic spontaneous urticaria in adults. It will evaluate whether it is safe, well tolerated and effective and also explore how remibrutinib acts in the body and on the skin.

The purpose of the study is to find out if YTB323 is safe and effective (if it can help) in people with SLE and NL.

The objective of this study is to test an investigational new treatment for participants with non-small cell lung cancer.

The purpose of the study, which involves research, is to determine whether VRDN-003, the experimental investigational drug, is safe and tolerable (i.e., whether the body reacts acceptably to VRDN-003) in participants with EOT when administered as a series of subcutaneous (SC) injections (given by needle into the layer of fat between the skin and muscle).

The main objective is to evaluate the efficacy of BAY 2927088 in objective response rate (ORR) assessed by blinded independent centralized review (BICR).

The study is being conducted to answer the following questions: What is the highest dose of ART0380 that can be administered along with a standard dose of gemcitabine to cancer patients without causing significant side effects (also known as the "recommended dose")? How often can the study products be administered to cancer patients? What are the side effects of each of the study products? What are the side effects of the combination? How do the study products affect biomarkers? Can th...

The main objective is to evaluate the efficacy of R-DXd treatment as measured by ORR as assessed by the investigator.

The objective of this study is to determine the most appropriate dose of BI 764532 to be received in the future by patients with a cancer like yours who progressed after treatment with available standard treatments, including platinum therapy, or who are ineligible for available standard treatments. Only patients confirmed positive for a tumor marker called "DLL3" will be eligible for treatment with BI 764532 in this study.